Naïve patients
(N=407)
Switch
(N=696)
Failure
(N=601)
Total
(N=1704)
Sex, N (%) men 295 (72.5) 483 (69.4) 398 (66.2) 1176 (69)
Age, median [Q1-Q3] years 41 [23.5-48] 44 [38-50] 42 [36-48] 43 [36-49]
Lenght of known infection, median [Q1-Q3] years 2 [0.3-7.8] 9.2 [4-14.6] 11.5 [6.6-16] 8.7 [2.9-14.5]
Hepatitis co-infection, N (%) 83 (20.4) 161 (23.1) 167 (27.8) 411 (24.1)
Previous CDC class C event, N (%) 85 (20.9) 209   (30) 179 (29.8) 473 (27.8)
Baseline VL, median [Q1-Q3] log10 copies/mL 4.8 [4.1 – 5.3] 1.6 [1.6 – 1.6] 3.9 [2.6 – 4.8] 2.5 [1.7 – 4.5]
Patients with baseline VL ≥ 5 log10 copies/mL (%) 41.2 - 18.5 15.1
Baseline CD4 cells/mm3, median [Q1-Q3] 239,2 [111-319] 512,4 [345-670] 286 [167-456] 354,7 [211-558]
Baseline CD4 cells <200/mm3 (%) 40.4 8.1 30.8 23
Nadir CD4 cells/mm3, median [Q1-Q3] 222 [104-289] 177 [71-264] 174 [64-261] 184 [74-272]
Number of previous regimens, median [Q1-Q3] - 3 [1-5] 3 [2-5] 3 [3-5]
Treatment strategies
3 drugs in the regimen, N (%) 373 (92) 664 (95) 485 (81) 1522 (89)
ABC/3TC + 1 NNRTI, N (%) 36 (9) 241 (35) 49 (8) 326 (19)
ABC/3TC + 1 bPI, N (%) 211 (52) 279 (40) 301 (50) 791 (46)
ABC/3TC + AZT, N (%) 119 (29) 115 (16) 117 (19.5) 351 (21)
Other, N (%) 7 (2) 29 (4) 18 (3.5) 54 (3)
4 drugs or more in the regimen, N (%) 32 (8) 26 (4) 113 (19) 171 (10)
“Naïve patients”: ABC/3TC used as part of the first regimen, “switch”: as part of a switch strategy in patients with VL below detection, “failure” as part of a rescue regimen
in patients with a previous failing regimen; VL=viral load
Table 1: Patients characteristics at baseline.
Goto home»